Ga-NODAGA-SNA014

Phase 1Small molecule

SSmartNuclide Biopharma

Ga-NODAGA-SNA014 is one of 39 small molecule programs targeting Phase II. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phase IINot yet recruiting

Phase IIPhase 1

Not yet recruiting

Competition

Competitive Landscape

40 competitors in Phase II

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 3

1 2

Rituxan

Roche

Phase 2

4 3

Lynparza

AstraZeneca

Phase 2

2 4

Eloxatin

Teva

Phase 2

2 5

Polivy

Roche

Phase 2

1 6

Imfinzi

AstraZeneca

Phase 2

1 7

Avastin

Roche

Phase 2

1 8

Adriamycin

Pfizer

Phase 2

1 9

Calquence

AstraZeneca

Phase 2

1 10

LUNSUMIO

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Phase II1 trial

Phase IIT Trial of SNA014

Not yet recruiting·SSmartNuclide Biopharma·Phase 1·NCT06646783·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ga-NODAGA-SNA014. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ga-NODAGA-SNA014 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ga-NODAGA-SNA014. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SmartNuclide Biopharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSmartNuclide Biopharma

Ga-NODAGA-SNA014

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Phase II1 trial

References

Drug Info

Quick Facts

Related News